SANDOSTATIN® LAR® is indicated for the treatment of:
- Patients with symptoms associated with functional gastro-entero-pancreatic endocrine tumours (e.g. carcinoid tumours with features of the carcinoid syndrome) or patients with advanced neuroendocrine tumours of the midgut or of unknown primary origin where non-midgut sites of origin have been excluded.1
- Patients with acromegaly in whom surgery is inappropriate or ineffective, or in the interim period until radiotherapy becomes fully effective.1
- SANDOSTATIN® LAR® Summary of Product Characteristics. December 2020.